The effect of short-term proton pump inhibitor plus anti-ulcer drug on the healing of endoscopic submucosal dissection-derived artificial ulcer: a randomized controlled trial.
Hepatogastroenterology
; 62(137): 219-24, 2015.
Article
em En
| MEDLINE
| ID: mdl-25911899
ABSTRACT
BACKGROUND/AIMS:
Artificial ulcers remain a major complication after Endoscopic submucosal dissection (ESD). The development of more effective treatment regimen for this ulcer is required than the use of proton pump inhibitor (PPI) alone.METHODOLOGY:
Patients with ESD-derived artificial ulcers were randomly assigned to two groups a group of patients who received rabeprazole 20 mg daily for 8 weeks (PPI group) and a group of patients who received a combination of rebamipide 300 mg daily for 8 weeks and rabeprazole 20 mg dairy for the first 4 weeks (reb+PPI group). The area reduction ratio and healing status of ulcers were evaluated endoscopically on postoperative 7, 28 and 56 days.RESULTS:
The overall ulcer area reduction ratio was higher in the reb+PPI group than in the PPI group, especially at an early stage. The ratio of progression to the H1 stage in the reb+PPI group was significantly higher than that in the PPI group, especially at an early stage.CONCLUSIONS:
Treatment with 8 weeks of rebamipide plus the first 4 weeks of PPI demonstrated a reduction ratio of artificial ulcers superior to that with 8 weeks of PPI mono-therapy. This combination treatment is, therefore, one of the candidate treatment strategies against ESD-derived artificial ulcers.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Gástricas
/
Úlcera Gástrica
/
Cicatrização
/
Gastroscopia
/
Quinolonas
/
Alanina
/
Dissecação
/
Inibidores da Bomba de Prótons
/
Rabeprazol
/
Gastrectomia
Tipo de estudo:
Clinical_trials
/
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
País como assunto:
Asia
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article